Holen Sie sich die Stockscreener-App
2.91
3.64%
-0.11
Handel nachbörslich:
2.91
Schlusskurs vom Vortag:
$3.02
Offen:
$3
24-Stunden-Volumen:
33,024
Relative Volume:
0.35
Marktkapitalisierung:
$208.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.64M
KGV:
-6.7674
EPS:
-0.43
Netto-Cashflow:
$-39.43M
1W Leistung:
+6.20%
1M Leistung:
-17.56%
6M Leistung:
+24.36%
1J Leistung:
-3.00%
1-Tages-Spanne:
$2.85
$3.04
1-Wochen-Bereich:
$2.46
$3.14
52-Wochen-Spanne:
$1.75
$4.3866
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Firmenname
Alpha Tau Medical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie DRTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
2.91 | 208.14M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-04-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-04-08 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-04 | Eingeleitet | Citigroup | Buy |
Alpha Tau Medical Ltd Aktie (DRTS) Neueste Nachrichten
March 2025 Penny Stocks To Consider For Growth - Yahoo Finance
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences - TipRanks
Alpha Tau to Participate in March Investor Conferences - The Manila Times
Looking to Meet Alpha Tau's Management? CFO Available at These March Conferences - StockTitan
Alpha Tau Achieves MDSAP Certification, Boosting Global Expansion Efforts - TipRanks
Alpha Tau Medical Gets Medical Device Single Audit Program Certification -February 24, 2025 at 10:37 am EST - Marketscreener.com
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification - The Manila Times
Can This New Medical Certification Transform Alpha Tau's Cancer Treatment Rollout? - StockTitan
Locally Advanced Pancreatic Cancer Market to Reach New Heights - openPR
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
Alpha Tau Announces FDA Approval of IDE Supplement to - GlobeNewswire
Alpha Tau Medical Gets FDA Approval to Expand DaRT Study in Pancreatic Cancer - Marketscreener.com
Alpha Tau Medical Ltd. Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT®? to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease - Marketscreener.com
Alpha Tau Gains FDA Approval to Expand Pancreatic Cancer Trial - TipRanks
Major Clinical Trial Expansion: Alpha Tau Doubles Down on Revolutionary Pancreatic Cancer Treatment - StockTitan
Alpha Emitter Market Projected To Witness Massive Growth, - openPR
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day - GlobeNewswire
Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials - TipRanks
Alpha Tau shares interim data across multiple clinical trials at R&D Update Day - TipRanks
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials -January 27, 2025 at 09:02 am EST - Marketscreener.com
Alpha Tau's Cancer Therapy Shows Breakthrough Results in Multiple Clinical Trials - StockTitan
Alpha Tau Medical (NASDAQ:DRTSW) Stock Price Up 14.3% – Still a Buy? - Defense World
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Rises By 7.1% - MarketBeat
Takeout news crowns JPM’s winning stocks - BioCentury
DRTS Stock Touches 52-Week High at $3.43 Amid Sector Growth - Investing.com
DRTS Stock Touches 52-Week High at $3.43 Amid Sector Growth By Investing.com - Investing.com South Africa
US Penny Stocks To Consider In January 2025 - Simply Wall St
Alpha Tau Medical (NASDAQ:DRTSW) Stock Price Up 14.3% – Should You Buy? - Defense World
Alpha Tau to Present Groundbreaking Cancer Therapy Data at ASCO Symposium - TipRanks
Alpha Tau Announces Upcoming Presentation of New Data at - GlobeNewswire
Alpha Tau Medical to Unveil Groundbreaking Cancer Therapy Data at ASCO GI Symposium - StockTitan
Alpha Tau Medical Ltd. Announces Board Changes - Marketscreener.com
Comparing Integra LifeSciences (NASDAQ:IART) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Alpha Tau Medical (NASDAQ:DRTS) Stock Price Up 1% – Should You Buy? - Defense World
Alpha Tau Medical Announces Board Leadership Changes Amid Strategic Expansion - TipRanks
Alpha Tau Medical Ltd. Announces Key Shareholder Decisions at Annual Meeting - TipRanks
Alpha Tau Announces Appointment of Maya Netser to its Board - GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor - Quantisnow
Alpha Tau Medical (NASDAQ:DRTS) Trading Up 1%Should You Buy? - MarketBeat
Alpha Emitter Market Set to Witness Steady Growth through (2024-2031) - WhaTech
Alpha Tau to Present at J.P. Morgan Healthcare Conference - TipRanks
DRTSAlpha Tau Medical Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Alpha Tau Medical to Present Cancer Therapy Breakthroughs at J.P. Morgan Healthcare Conference - StockTitan
Alpha Tau to Showcase Innovations at Oncology Symposium - TipRanks
Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium - The Manila Times
Alpha Tau Medical : to Participate in Ladenburg’s Oncology Innovators & Investors Symposium Form 6 K - Marketscreener.com
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium - Marketscreener.com
Alpha Tau Medical to Present Alpha DaRT Cancer Therapy at Ladenburg Oncology Symposium - StockTitan
Finanzdaten der Alpha Tau Medical Ltd-Aktie (DRTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):